Massive spontaneous bleeding

Authors

  • Alberto J. Alfaro Murillo Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia
  • Carlos Dobles Ramírez Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia
  • Donato A. Salas Segura Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia

DOI:

https://doi.org/10.51481/amc.v59i4.983

Keywords:

Hemorrhage, Factor VIII, plasmapheresis, spontaneous bleeding, acquired hemophilia

Abstract

A patient that presented with spontaneous hemorrhagic diathesis, with no apparent cause is presented. Hemorrhagic diathesis presents a wide range of diagnosis possibilities as of coagulation disorders are referred, in the context of a healthy patient with no previous major bleeding episodes and that debuts with massive hemorrhages. Acquired hemophilia, a little known disease, is one that must be considered. Acquired hemophilia is an uncommon hemostasis disorder characterized by the presence of acquired inhibitors of coagulation factors in the plasma of the sick patient. These acquired inhibitors, are antibodies that could be alloantibodies or autoantibodies. Alloantibodies are developed in patients who have coagulation factor deficiency, in response to factor replacement therapy, thus complicating treatment. On the other hand, autoantibodies are developed in people without previous defects and are specific against a factor of coagulation, affecting or not their function, obstructing one or several stages of the coagulation pathways. We report a case of acquired hemophilia due to an autoantibody against factor VIII in a 58 years old male patient with spontaneous massive bleeding.

Downloads

Download data is not yet available.

References

Lucía Remotti, Silvia Haydée, Marcelo Feancisco. Inhibidores adquiridos de la coagulación: enfoque diagnóstico y casos especiales. ABCL 2016;50: 291-301

Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, et al. AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus 2015;13:498513.

Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 2012; 38: 447-53.

Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.

Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, et al. ‘Criteria' aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011; 20; 182-90.

Blanco A. Inhibidores adquiridos de la coagulación y otros desórdenes inmunológicos. En: Blanco A, Kordich L, Bermejo E, Forastiero R, Lauricella AM, Pieroni G, Quintana I, Scazziota A, editores. Fundamentos para el manejo práctico en el laboratorio de hemostasia. 2da. ed. La Plata: Federación Bioquímica de la Provincia de Buenos Aires; 2013. p 517-83.

Kershaw G, Favaloro EJ. Laboratory identification of factor inhibitors: an update. Pathology 2012; 44: 293- 302.

Favaloro EJ, Verbruggen B, Miller CH. Laboratory testing for factor inhibitors. Haemophilia 2014; 20 Suppl 4: 94-8.

W Collins P, Chalmers E, Hart D, Jennings I, Liesner R, Rangarajan S, et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162: 758-73.

Published

2017-11-20 — Updated on 2017-11-20

Versions

How to Cite

Massive spontaneous bleeding. (2017). Acta Médica Costarricense , 59(4), 164-166. https://doi.org/10.51481/amc.v59i4.983